ANC28.1 mAb as a stimulating agent in a Cytokine Release Assay for assessment of preclinical safety

By /

“Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies” Natasha Helleberg Madsen, Monika Gad, Jesper Larsen. (Feb 5, 2022) J Immunol Methods 502: 113231. https://doi.org/10.10

PBMC were stimulated with immobilized ANC28.1, CD28.1 and muromonab CD3. Assessed Cytokines and levels of Activation molecules by flow could determine the potential of Cytokine Storm after biological drug treatment.

Ancell anti-human CD28 (clone ANC28.1) Products